AARD: Aardvark Therapeutics Inc Company Short-Term Debt

Symbol and logo of brand Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc (AARD) develops therapies for metabolic disorders, with management focusing on an innovative drug targeting obesity and hereditary pathologies. This chart reflects that the asset's value on GURU.Markets is 0.00, although the business faces intense pressure from market leaders, concerns regarding the outcome of Phase II trials, and an acute need for investment.

AARD (Aardvark Therapeutics Inc.) Company Short-Term Debts history from 02/14/2025 to 11/01/2026

AARD (Aardvark Pharma): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Aardvark Therapeutics|AARD - Fair Value Consensus
- market capitalization information:
Market Value Aardvark Therapeutics Inc|AARD - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Aardvark Therapeutics|AARD - Book Capitalization|Market Cap to Net Assets Ratio aardvarktherapeutics.com|AARD - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Aardvark Therapeutics Inc|AARD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Aardvark Therapeutics Inc|AARD - Company Cumulative Debt|Debt to Book Value Aardvark Therapeutics Inc|AARD - Amount of Long-Term Liabilities|Company Short-Term Debts Aardvark Therapeutics|Quick Ratio aardvarktherapeutics.com
- net income and valuation multiples indicators:
AARD - Company Net Income
Basic company analysis:Aardvark Therapeutics - AARD
Mass-produced product of Aardvark Pharma

Short-term debt measures the total financial obligations of a company with a maturity of up to one year. For Aardvark Therapeutics Inc (AARD), which lacks operating revenue, this metric reflects the pressure on existing cash reserves. Analyzing the short-term debt balance allows for filtering out market noise and assessing the actual burn rate. Payment dynamics determine liquidity risk during the conduct of clinical trials. Consistently low debt confirms asset preservation but limits the pace of expansion.

Who Aardvark Therapeutics Inc competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Corcept (CORT) - Company Short-Term Debt|Company Current Liabilities Rhythm Corp|AKRO (Akero Therapeutics) - Company Short-Term Debts|Company Short-Term Debts metsera.com|Company Current Liabilities MLTX (MoonLake)|CRNX (Crinetics Pharmaceuticals, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt NewAmsterdam Pharma N.V. NAMS|SLNO - Company Current Liabilities|Amicus Therapeutics - Company Short-Term Debts|Short-Term Debt 89bio.com|AGIO (Agios Pharmaceuticals, Inc.) - Company Current Liabilities|GPCR: Amount of Current Liabilities|MDXG (MiMedx Group) - Company Short-Term Debts|Company Short-Term Debts Rezolute Bio|Company Short-Term Debts LXRX|Company Short-Term Debt MBX (mbxbio.com)|Company Short-Term Debt Altimmune ALT|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|Company Short-Term Debts Matinas BioPharma Holdings, Inc. MTNB|Spruce Biosciences - Company Short-Term Debts|GLTO - Company Short-Term Debts|Carmell Corp (CTCX) - Company Short-Term Debt|Lumos Therapeutics - Company Short-Term Loans and Borrowings|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Short-Term Indebtedness RDUS (radiuspharm.com)